Micronutrient status of individuals with overweight and obesity following 3 months' supplementation with PolyGlycopleX (PGX®) or psyllium: a randomized controlled trial.
Absorption
Bioavailability
Deficiency
Dietary fibre
Micronutrients
Obesity
PGX®
Psyllium
Journal
BMC nutrition
ISSN: 2055-0928
Titre abrégé: BMC Nutr
Pays: England
ID NLM: 101672434
Informations de publication
Date de publication:
03 May 2022
03 May 2022
Historique:
received:
17
02
2021
accepted:
08
04
2022
entrez:
3
5
2022
pubmed:
4
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Safe and effective weight control strategies are needed to curtail the current obesity epidemic worldwide. Increasing dietary fibre has shown positive results with weight loss as well as in the reduction of metabolic syndrome risk factors. However, fibre can act as an inhibitor to the bioavailability of micronutrients in the gastrointestinal tract. While there is a substantial amount of scientific research into psyllium fibre, PolyGlycopleX (PGX®) is a novel fibre and as yet the effects of PGX® on micronutrient status is not well researched. To determine whether 3-months' supplementation with 15 g of psyllium or PGX® fibre daily affects micronutrient status of overweight and obese adults. Overweight and obese individuals with a BMI between 25-40 kg/m No significant differences between fibre supplement groups and micronutrient status were found after 3 months at p > 0.05. Dietary intake of vitamin C was significantly lower for PGX® at 3 months compared to baseline and compared to control (p < 0.05). Folate was significantly lower in the control group after 3 months (p < 0.05). In the psyllium group, folate, sodium, zinc and magnesium intake decreased after 3 months (p < 0.05). A limitation of dietary intake data (tertiary measure) is the potential for inaccurate self-reporting, although reduced nutrient intake could be due to the satiating effect of dietary fibre. There were no significant between group differences in serum micronutrient concentrations after a 3-month psyllium fibre or PGX® supplementation intervention of 15 g per day. Fibre supplementation is unlikely to compromise the nutritional status of overweight and obese individuals in the short term. Further research is recommended to monitor micronutrient status over a longer period or with a higher fibre dosage.
Sections du résumé
BACKGROUND
BACKGROUND
Safe and effective weight control strategies are needed to curtail the current obesity epidemic worldwide. Increasing dietary fibre has shown positive results with weight loss as well as in the reduction of metabolic syndrome risk factors. However, fibre can act as an inhibitor to the bioavailability of micronutrients in the gastrointestinal tract. While there is a substantial amount of scientific research into psyllium fibre, PolyGlycopleX (PGX®) is a novel fibre and as yet the effects of PGX® on micronutrient status is not well researched.
AIM
OBJECTIVE
To determine whether 3-months' supplementation with 15 g of psyllium or PGX® fibre daily affects micronutrient status of overweight and obese adults.
METHODS
METHODS
Overweight and obese individuals with a BMI between 25-40 kg/m
RESULTS
RESULTS
No significant differences between fibre supplement groups and micronutrient status were found after 3 months at p > 0.05. Dietary intake of vitamin C was significantly lower for PGX® at 3 months compared to baseline and compared to control (p < 0.05). Folate was significantly lower in the control group after 3 months (p < 0.05). In the psyllium group, folate, sodium, zinc and magnesium intake decreased after 3 months (p < 0.05). A limitation of dietary intake data (tertiary measure) is the potential for inaccurate self-reporting, although reduced nutrient intake could be due to the satiating effect of dietary fibre.
CONCLUSIONS
CONCLUSIONS
There were no significant between group differences in serum micronutrient concentrations after a 3-month psyllium fibre or PGX® supplementation intervention of 15 g per day. Fibre supplementation is unlikely to compromise the nutritional status of overweight and obese individuals in the short term. Further research is recommended to monitor micronutrient status over a longer period or with a higher fibre dosage.
Identifiants
pubmed: 35505399
doi: 10.1186/s40795-022-00534-7
pii: 10.1186/s40795-022-00534-7
pmc: PMC9063372
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42Informations de copyright
© 2022. The Author(s).
Références
Nutr Rev. 2009 Oct;67(10):559-72
pubmed: 19785688
Nutr J. 2010 Nov 22;9:58
pubmed: 21092221
Gut. 1994 Dec;35(12):1747-52
pubmed: 7829013
Int J Obes Relat Metab Disord. 2004 Jul;28(7):920-4
pubmed: 15098017
ISRN Endocrinol. 2012;2012:103472
pubmed: 22462011
Br J Nutr. 2006 Mar;95(3):640-9
pubmed: 16512951
Clin Gastroenterol Hepatol. 2017 May;15(5):712-719.e4
pubmed: 27080737
Int Wound J. 2018 Apr;15(2):311-312
pubmed: 29266777
Aliment Pharmacol Ther. 1997 Dec;11(6):1067-72
pubmed: 9663831
J Food Sci. 2007 Mar;72(2):R21-32
pubmed: 17995848
Am J Clin Nutr. 2018 Mar 1;107(3):436-444
pubmed: 29566200
J Nutr. 2013 Jul;143(7):1036-45
pubmed: 23700340
J Health Psychol. 2019 Dec;24(14):2042-2059
pubmed: 28810493
Nutr Metab (Lond). 2016 Nov 17;13:82
pubmed: 27891167
Int J Obes Relat Metab Disord. 2002 Dec;26 Suppl 4:S2-4
pubmed: 12457290
Nutrients. 2017 Jan 29;9(2):
pubmed: 28146065
Adv Nutr. 2011 May;2(3):293-4
pubmed: 22332062
Am J Clin Nutr. 1992 Mar;55(3):719-22
pubmed: 1312763
Obes Rev. 2012 Nov;13(11):1034-47
pubmed: 22863407
J Clin Endocrinol Metab. 2005 Jul;90(7):4119-23
pubmed: 15855256
Nutrients. 2017 Apr 20;9(4):
pubmed: 28425944
J Am Diet Assoc. 2006 Aug;106(8):1172-80
pubmed: 16863711
Nutr J. 2009 Feb 05;8:9
pubmed: 19196472
Crit Care Med. 2015 Jan;43(1):240-1
pubmed: 25514714
J R Soc Promot Health. 2000 Dec;120(4):242-7
pubmed: 11197452
Nutr Rev. 2009 Apr;67(4):188-205
pubmed: 19335713
Am J Gastroenterol. 1992 Mar;87(3):305-10
pubmed: 1311494
Br J Nutr. 2011 Jan;105(1):90-100
pubmed: 20727237
Nutr Today. 2015 Mar;50(2):82-89
pubmed: 25972618